Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 1, 90-98, January 2007; doi:10.1634/theoncologist.12-1-90
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sequist, L. V.
Right arrow Articles by Lynch, T. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sequist, L. V.
Right arrow Articles by Lynch, T. J.

Lung Cancer

Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing

Lecia V. Sequist, Victoria A. Joshi, Pasi A. Jänne, Alona Muzikansky, Panos Fidias, Matthew Meyerson, Daniel A. Haber, Raju Kucherlapati, Bruce E. Johnson, Thomas J. Lynch

Massachusetts General Hospital Cancer Center, Harvard Medical School/Partners HealthCare Center for Genetics and Genomics, Massachusetts General Hospital Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Key Words. Lung cancer • EGFR • Mutation • Genetic screening

Correspondence: Lecia V. Sequist, M.D., MPH, MGH Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA. Telephone: 617-724-4000; Fax: 617-726-0453; e-mail: lvsequist{at}partners.org

Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response and prolonged survival in patients with non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). We began screening patients for somatic EGFR mutations by DNA sequencing as part of clinical care in 2004. We performed a retrospective cohort study of 278 patients with NSCLC referred for EGFR testing over a 10-month period. Tumor samples underwent direct DNA sequence analyses of EGFR exons 18 through 24. We determined the clinical characteristics and EGFR mutation status of the patients and analyzed their response to therapy and survival. EGFR somatic mutations were identified in 68 (24%) of patients. A minimal smoking history was the strongest clinical predictor of harboring a mutation. In multivariable analyses, each pack-year of smoking corresponded to a 5% decreased likelihood of having an EGFR mutation. Among 92 patients with unresectable disease undergoing subsequent systemic therapy, EGFR mutations were associated with an increased response rate to EGFR TKIs (p < .0001) but not chemotherapy. Overall survival was significantly prolonged in EGFR mutation-positive patients (p = .001), with a median survival of 3.1 years compared with 1.6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information.




This article has been cited by other articles:


Home page
 JCOHome page
J.-Y. Douillard, F. A. Shepherd, V. Hirsh, T. Mok, M. A. Socinski, R. Gervais, M.-L. Liao, H. Bischoff, M. Reck, M. V. Sellers, et al.
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
J. Clin. Oncol., February 10, 2010; 28(5): 744 - 752.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Lara-Guerra, T. K. Waddell, M. A. Salvarrey, A. M. Joshua, C. T. Chung, N. Paul, S. Boerner, A. Sakurada, O. Ludkovski, C. Ma, et al.
Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 20, 2009; 27(36): 6229 - 6236.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A Fassina, A Gazziero, D Zardo, M Corradin, E Aldighieri, and G P Rossi
Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis
J. Clin. Pathol., December 1, 2009; 62(12): 1096 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
M. C. GARASSINO, K. BORGONOVO, A. ROSSI, A. MANCUSO, O. MARTELLI, A. TINAZZI, S. DI COSIMO, N. LA VERDE, P. SBURLATI, C. BIANCHI, et al.
Biological and Clinical Features in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-analysis
Anticancer Res, July 1, 2009; 29(7): 2691 - 2701.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. D. RICE, J. E. BUSH, and S. L. BROWER
Assessment of Erlotinib in Chemoresponse Assay
Anticancer Res, June 1, 2009; 29(6): 1993 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, M. Bavieri, B. Murer, E. Meschiari, S. Tamberi, et al.
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Am J Clin Pathol, April 1, 2009; 131(4): 478 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. B. Costa, K.-S. H. Nguyen, B. C. Cho, L. V. Sequist, D. M. Jackman, G. J. Riely, B. Y. Yeap, B. Halmos, J. H. Kim, P. A. Janne, et al.
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Clin. Cancer Res., November 1, 2008; 14(21): 7060 - 7067.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Maruyama, Y. Nishiwaki, T. Tamura, N. Yamamoto, M. Tsuboi, K. Nakagawa, T. Shinkai, S. Negoro, F. Imamura, K. Eguchi, et al.
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 10, 2008; 26(26): 4244 - 4252.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. P. Regala, E. A. Thompson, and A. P. Fields
Atypical Protein Kinase C{iota} Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells
Cancer Res., July 15, 2008; 68(14): 5888 - 5895.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. W. Bell, B. W. Brannigan, K. Matsuo, D. M. Finkelstein, R. Sordella, J. Settleman, T. Mitsudomi, and D. A. Haber
Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms
Clin. Cancer Res., July 1, 2008; 14(13): 4079 - 4084.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Eberhard, G. Giaccone, and B. E. Johnson
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
J. Clin. Oncol., February 20, 2008; 26(6): 983 - 994.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
K. E. Finberg, L. V. Sequist, V. A. Joshi, A. Muzikansky, J. M. Miller, M. Han, J. Beheshti, L. R. Chirieac, E. J. Mark, and A. J. Iafrate
Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features
J. Mol. Diagn., July 1, 2007; 9(3): 320 - 326.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. A. Chabner and T. G. Roberts
The FDA in 2006: Reasons for Optimism
Oncologist, March 1, 2007; 12(3): 247 - 249.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement